About this approach
NanoKnife is a device used for irreversible electroporation, or IRE. A clinician places needle electrodes around a planned target and delivers brief electrical pulses that disrupt cell membranes without relying on heat or freezing. In prostate care, the current U.S. device indication includes ablation of prostate tissue. Evaluation commonly uses biopsy, MRI, PSA, cancer grade, location, and disease extent to decide whether a focal treatment plan is technically appropriate.
Where it fits: Focal ablation of selected prostate tissue, including use in localized intermediate-risk prostate cancer programs
Where this treatment is used
The FDA cleared the NanoKnife System in December 2024 for surgical ablation of soft tissue including prostate tissue. The prospective, nonrandomized PRESERVE study treated 121 people with organ-confined grade-group 2 or 3 prostate cancer. At 12 months, 71% had a negative biopsy within the treated field; 14 participants had grade 3 or higher adverse events, including three procedure-related grade 3 events. These results document focal prostate-tissue ablation and one-year follow-up.
Procedure and practical considerations
Treatment requires anesthesia and carefully placed electrodes.
Clinics reporting this approach
These clinic profiles connect to this approach through clinic-confirmed selections or Cancer Clinic Finder’s source review. Open a profile to compare locations, services, practical details, and ways to get started.
119 connected profiles
Browse all 119 connected profilesSources
Source information checked: 2026-10-01. The links below identify the public and clinic-provided materials used for this page.
- FDA 510(k) K242687: NanoKnife indication including prostate tissue ↗Checked 2026-10-01
- George et al., European Urology: final PRESERVE trial results ↗Checked 2026-10-01
- NanoKnife public physician locator ↗Checked 2026-10-01
How Cancer Clinic Finder compiles information · Suggest a factual correction